Employers can protect themselves by considering key aspects of their benefits programs.

The health insurer group’s new employer-provided coverage primer ends with a plea for stability.

Axos Bank says an OptumInsight employee submitted fraudulent invoices to his company’s factoring provider.

U.S. companies expect GLP-1 agonists and biologics like Humira to push prices up at the highest rate since at least 2010.

33% of plan sponsors do not even ask for coverage offers from multiple contractors.

The CEO of Voya says the company will “focus on the discipline of margin improvement over any type of premium growth.”

The firm sees the astonishingly high cost of “cellular, gene, and RNA therapies”—high-tech treatments for conditions like sickle cell disease—as an emerging threat to group health plan budgets.

The American Benefits Council found most that voters back current rules, while America’s Health Insurance Plans found bipartisan support.